Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$35.84

1.41 (4.10%)

07:28
05/19/17
05/19
07:28
05/19/17
07:28

Sarepta worked with parents to get FDA approval for eteplirsen, WSJ says

After trial data for Duchenne muscular dystrophy treatment eteplirsen proved inconclusive, Sarepta Therapeutics worked with parents of sick boys to provide testimony to the Food and Drug Administration supporting the drug's approval, the Wall Street Journal reports, citing parents, company managers and a Sarepta consultant. An FDA advisory committee, the majority of which didn't know Sarepta's involvement with the families, voted against approval 7-6 last year, however it was later overturned. Reference Link

SRPT Sarepta
$35.84

1.41 (4.10%)

05/18/17
PIPR
05/18/17
NO CHANGE
Target $43
PIPR
Overweight
Piper sees limited impact on Sarepta sales from FDA vote
Piper Jaffray analyst Edward Tenthoff sees a limited impact on sales from the FDA's unanimous vote allowing the use of central venous catheters to administer exon skipping drugs SRP-4045 and SRP-4053 in the Phase III ESSENCE trial. The use of IV ports will benefit DMD boys experiencing pain and trauma related to intravenous injection, and potentially lower discontinuation rates, but not impact Exondys51 sales in the near-term, Tenthoff tells investors in a research note. He keeps an Overweight rating on Sarepta Therapeutics with a $43 price target.
05/12/17
PIPR
05/12/17
NO CHANGE
Target $43
PIPR
Overweight
Sarepta panel should not impact planned interim analysis, says Piper Jaffray
After the FDA posted briefing documents ahead of a joint meeting on May 18 to vote on a parent's request for the inclusion of alternative venous access device in Sarepta's Phase III ESSENCE study of SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff said the decision should not impact the planned interim efficacy analysis after 48-week data are available, but a "Yes" vote would be beneficial for DMD boys and potentially lower discontinuation rates. He maintains his $43 price target and Overweight rating on Sarepta shares.
04/28/17
LEER
04/28/17
NO CHANGE
Target $52
LEER
Outperform
Sarepta price target raised to $52 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta to $52 from $47 after the company reported $16.3M in Exondys51 sales in Q1 that beat estimates and easily surpassed the company's guidance. The analyst reiterates an Outperform rating on the shares.
04/26/17
JANY
04/26/17
NO CHANGE
Target $65
JANY
Buy
Janney sees Sarepta selling off without material guidance raise
Going into tomorrow's earnings report from Sarepta Therapeutics, the Street is expecting a significant increase to FY17 guidance, which may not materialize, Janney Capital analyst Debjit Chattopadhyay tells investors in a pre-earnings research note. The FY17 consensus estimate for Exondys51 sales is $96M versus management's guidance of $80M-plus, the analyst points out. Chattopadhyay believes Sarepta shares could be pressured if guidance is not materially higher than the consensus since the stock is up $7 since April 11. The analyst continues to like Sarepta's intermediate to long-term outlook and recommends buying the shares on any meaningful pullbacks. Chattopadhyay has a Buy rating on the shares with a $65 fair value estimate. Sarepta in morning trading is down 58c to $35.23.

TODAY'S FREE FLY STORIES

INTU

Intuit

$127.16

1.78 (1.42%)

14:49
05/23/17
05/23
14:49
05/23/17
14:49
Options
Intuit options imply 5.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.92

0.08 (0.06%)

14:47
05/23/17
05/23
14:47
05/23/17
14:47
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

, RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
Breaking Periodicals news story on Canadian Natural, Royal Dutch Shell, Royal Dutch Shell »

Shell to sell entire 8.8%…

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

RDS.B

Royal Dutch Shell

$56.96

-0.0576 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$113.64

0.77 (0.68%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
CBS LA teases 'shocking' report on Sempra's Aliso Canyon gas leak »

CBS Los Angeles tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

X

U.S. Steel

$20.43

0.96 (4.93%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Technical Analysis
Technical Analysis: U.S. Steel breaking out of downtrend, levels to watch »

The stock is rallying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.70

-0.14 (-0.11%)

14:42
05/23/17
05/23
14:42
05/23/17
14:42
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says thinks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

X

U.S. Steel

$20.39

0.9169 (4.71%)

14:40
05/23/17
05/23
14:40
05/23/17
14:40
Options
US Steel calls outpace puts nearly 3:1 as shares rally »

US Steel calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Downgrade
Momo rating change  »

Momo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AZO

AutoZone

$596.00

-63.49 (-9.63%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Recommendations
AutoZone analyst commentary  »

AutoZone weakness an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.63

-0.21 (-0.16%)

14:37
05/23/17
05/23
14:37
05/23/17
14:37
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ALXN

Alexion

$115.42

1.58 (1.39%)

14:31
05/23/17
05/23
14:31
05/23/17
14:31
Recommendations
Alexion analyst commentary  »

Alexion should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

RBS

RBS

$6.95

0.09 (1.31%)

14:30
05/23/17
05/23
14:30
05/23/17
14:30
Options
Royal Bank of Scotland sees put buying »

Royal Bank of Scotland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:29
05/23/17
05/23
14:29
05/23/17
14:29
Hot Stocks
Honeywell says spinoff of aerospace is 'intriguing concept' »

This comment was made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$132.08

0.235 (0.18%)

14:25
05/23/17
05/23
14:25
05/23/17
14:25
Hot Stocks
Honeywell to shape portfolio changes over next 2-3 years »

Comments are from EPG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HLF

Herbalife

$69.44

-4 (-5.45%)

14:21
05/23/17
05/23
14:21
05/23/17
14:21
Technical Analysis
Technical Analysis: Herbalife falls on report China executive departs »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$80.28

10.21 (14.57%)

14:20
05/23/17
05/23
14:20
05/23/17
14:20
Options
Newsbots go Bungee jumping this afternoon »

Newsbots go Bungee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$122.18

0.52 (0.43%)

14:18
05/23/17
05/23
14:18
05/23/17
14:18
Hot Stocks
United Technologies CEO not interested in split »

Speaking at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Recommendations
Momo analyst commentary  »

Momo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

$NSD

NASDAQ Market Internals

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
05/23/17
05/23
14:16
05/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$61.56

0.175 (0.29%)

14:12
05/23/17
05/23
14:12
05/23/17
14:12
Hot Stocks
A.M. Best affirms AIG credit ratings, removes from under review »

A.M. Best has removed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BWLD

Buffalo Wild Wings

$150.60

-2 (-1.31%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Technical Analysis
Technical Analysis: Buffalo Wild Wings trades at session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.96

0.12 (0.09%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Earnings
Honeywell backs FY17 EPS view $6.90-$7.10, consensus $7.09 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:08
05/23/17
05/23
14:08
05/23/17
14:08
Earnings
Honeywell backs Q2 EPS view $1.75-$1.80, consensus $1.78 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WRB

W. R. Berkley

$67.93

0.26 (0.38%)

14:05
05/23/17
05/23
14:05
05/23/17
14:05
Hot Stocks
Ca. Insurance Commissioner announces $12M settlement with W. R. Berkley »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.